# Placebo Controlled Double-blind Dose Ranging Study of the Efficacy and Safety of SSR149744C 50, 100, 200 or 300 mg OD With Amiodarone as Calibrator for the Maintenance of Sinus Rhythm in Patients With Recent Atrial Fibrillation/Flutter

> **NCT00233441** · PHASE2,PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 673 (actual)

## Conditions studied

- Atrial Fibrillation
- Atrial Flutter

## Interventions

- **DRUG:** CELIVARONE (SSR149744C)

## Key facts

- **NCT ID:** NCT00233441
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** 2006-05
- **Final completion:** 2006-05
- **Target enrollment:** 673 (ACTUAL)
- **Last updated:** 2012-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00233441

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00233441, "Placebo Controlled Double-blind Dose Ranging Study of the Efficacy and Safety of SSR149744C 50, 100, 200 or 300 mg OD With Amiodarone as Calibrator for the Maintenance of Sinus Rhythm in Patients With Recent Atrial Fibrillation/Flutter". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00233441. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*